Vericel Corp. Awarded $196.8M HHS BARDA Contract For NonSurgical Debridement, Research And Development In Biotechnology (Except Nanobiotechnology)

Vericel Corp. has been awarded a contract worth $196.8 million from the HHS BARDA for non-surgical debridement and research and development in biotechnology, excluding nanobiotechnology. This contract is expected to enhance Vericel's capabilities in its field. The stock ticker for Vericel is VCEL.